secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elevation Oncology, Inc. (—)
CIK:        0001783032
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001104659-25-025878
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elevation Oncology halts EO-3021, lays off 70%, initiates strategic review
--------------------------------------------------------------------------

- Discontinued lead ADC EO-3021 after Phase 1 data showed 22.2% ORR and 72.2% DCR in biomarker-enriched gastric/GEJ cancer patients.
- Reducing workforce by ~70%; estimated $3M in cash costs, majority paid by June 2025. CMO Valerie Jansen departs March 31.
- Advancing EO-1022 (HER3 ADC) with glycan site-specific conjugation; IND filing targeted 2026, preclinical data at AACR 2025.
- Cash, cash equivalents and securities of $93.2M at Dec 31, 2024 fund operations into 2H 2026.
- Evaluating strategic options to maximize shareholder value in parallel with EO-1022 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/0001104659-25-025878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/tm259617d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-025878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer